Merck Healthcare KGaA

Oncology and solid tumor research

Clinical activity spans advanced solid tumors, non-small cell lung cancer, lung cancer, gastric cancer, pancreatic ductal adenocarcinoma, epithelial ovarian cancer, and colorectal cancer, with additional interest in metastatic and locally advanced unresectable tumors.

  • METex14 skipping alterations and MET amplification
  • EGFR-mutated lung cancer
  • CEACAM5-targeted solid tumor programs
  • DNA damage response and topoisomerase 1-based combinations

Research also includes head and neck squamous cell carcinoma, reflecting a broad oncology portfolio across thoracic, gastrointestinal, and upper aerodigestive malignancies.

Autoimmune disease and rheumatology

Trials address systemic lupus erythematosus, cutaneous lupus erythematosus, subacute cutaneous lupus, dermatomyositis, and polymyositis, with a focus on inflammatory disease activity and symptom control.

  • Lupus spectrum disorders
  • Inflammatory myopathies
  • Cutaneous autoimmune manifestations
  • Disease activity and tolerability in immune-mediated disease

The portfolio links systemic and skin-focused autoimmune conditions with broader immune modulation research.

Neuromuscular and rare immune-mediated disorders

Investigations include generalized myasthenia gravis, alongside autoimmune conditions that affect muscle strength and neuromuscular function.

  • Generalized myasthenia gravis
  • Autoimmune neuromuscular disease
  • Muscle weakness and functional impairment

This area extends the sponsor’s interest in immune-mediated disorders beyond dermatologic and systemic rheumatology indications.

Studies involve locally advanced squamous cell carcinoma of the head and neck and resected head and neck squamous cell carcinoma, with attention to treatment settings that include radiotherapy and postoperative disease control.

  • Head and neck squamous cell carcinoma
  • Resected and locally advanced disease
  • Radiation-based cancer treatment

These programs connect local-regional cancer management with systemic anti-cancer strategies.

Healthy volunteer and special population studies

Research also includes healthy volunteers, renal impairment cohorts, and reproductive health-related studies such as infertility and pituitary-suppressed female participants.

  • Renal impairment
  • Healthy participant studies
  • Female reproductive endocrinology
  • Pharmacokinetics in special populations

These trials support development across both disease-focused and population-specific clinical settings.

Want to learn more about this study or check if you can participate? Contact us.

Matched clinical trials

  • Study on Xevinapant and Radiotherapy for High-Risk Head and Neck Cancer Patients Unable to Take High-Dose Cisplatin

    Not recruiting

    3 1
    Investigated drugs:
    Austria Belgium Czechia France Germany Greece +6
  • Study of Enpatoran in Adults with Systemic Lupus Erythematosus (SLE) and Cutaneous Lupus Erythematosus (CLE)

    Not recruiting

    2 1
    Investigated drugs:
    Bulgaria Greece Poland Romania Spain
  • Study of Avelumab and Lenvatinib for Children with Central Nervous System Tumors

    Not recruiting

    1 1 1 1
    Investigated drugs:
    France Germany
  • Study of Tepotinib and Osimertinib for Patients with Advanced or Metastatic Lung Cancer Resistant to Osimertinib Therapy

    Not recruiting

    2 1 1 1
    Investigated drugs:
    Belgium France Germany Italy Spain
  • Study of Tepotinib for Patients with Advanced Lung Cancer with MET Exon 14 Skipping Alterations or MET Amplification

    Not recruiting

    2 1 1
    Investigated drugs:
    Belgium France Germany Italy The Netherlands Poland +1
  • Study of Tuvusertib and Cemiplimab for Patients with Non-Squamous Non-Small Cell Lung Cancer After Previous Treatments

    Not recruiting

    1 1 1 1
    Investigated diseases:
    Belgium France Germany Italy Spain